Duvelisib was the 2nd PI3K inhibitor authorised through the FDA, also based upon a stage III randomized trial.130 The efficacy and protection profile of your drug seem similar with All those of idelalisib, if not a bit beneficial. Regarding alternative BTK inhibitors, there are many products and solutions in advancement, https://tonyd975ucl2.cosmicwiki.com/user